Peli BioThermal, PAXAFE Partnership Signals AI-Powered Cold Chain Future

Peli BioThermal and PAXAFE are collaborating to pair cold chain packaging with AI-driven monitoring, signaling where pharma logistics technology is regulated next.

Peli BioThermal and PAXAFE announced a strategic collaboration that pairs cold chain packaging with AI-driven digital monitoring and prognostic analytics. The transaction provides a window into where health cold chain is heading over the next numerous years, as physical packaging and real-time intelligence progressively function as a single providing rather than specific devices.

How Does the Partnership Combine Packaging and Intelligence?

Under the collaboration, Peli BioThermal's packaging portfolio, involving the Crēdo Vault bulk shipper, CrēdoGO reusable shipper and DV10 dry vapor shipper, is paired with PAXAFE's intelligence platform for lane planning, real-time visibility, quality processes and predictive analytics. The organization describes the integration as covering the full spectrum of biopharmaceutical supply chain requirements, from physical protection in transit to intelligent analysis, alerting and compliance reporting.

Moreover, the collaboration spans an integrated footprint in 90 countries and covers joint competency in GDP, GMP and international frameworks involving ISO 9001 and EcoVadis sustainability recognition.

Both Companies framed the deal against an organizational backdrop of increasing government necessities and increasingly complex supply chains, pointing to shared consumers and markets and an end-to-end monitoring lifecycle running from smart tools in the sectors to cloud-based dashboards and automatic reporting as evidence that their assets are harmonizing.

"Peli BioThermal has built its reputation by being the partner life sciences companies can rely on when it matters most  protecting products at every stage of the cold chain," said Sam Herbert, CEO of Peli BioThermal, in a press release. "Together, we give the pharmaceutical industry something it has always needed: proven cold chain packaging reliability combined with the power of cutting-edge digital intelligence in a single, fully integrated solution."

Doug Ross, president and chief operating officer at Peli BioThermal, said the partnership brings together "trusted packaging expertise and advanced digital intelligence to deliver a smarter, more connected future for pharmaceutical logistics." "What we are building together is not a vendor association; it is a shared commitment to raising the standard of what integrated pharmaceutical supply chain monitoring can deliver,” added PAXAFE CEO, Ilya Preston.

Where Is Cold Chain Technology Headed Next?

The collaboration lands alongside a wider industry shift toward AI-driven control towers for cold chain, technology that ingests real-time sensor data in a distribution network and uses machine learning to predict delays or temperature risk before they materialize rather than simply logging what already happened. In repetition, that could mean a control tower flagging a rerouted flight while a winter storm and robotically prompting planners to deploy backup vessels or reassign doses from standby stock before a shipment is at risk

In a recent interview with Pharmaceutical Commerce, Joydeep Ganguly, chief processes and superiority officer at Agilent Technologies, noted operational effectiveness, improved resilience and sustainability as a region in which 4IR tools like AI will be leveraged in the pharmaceutical cold chain. At the time, Ganguly noted that “the pharmaceutical supply chain is currently navigating a period of radical restructuring,” moving away from the "efficiency-at-all-costs" model that defined the last 20 years toward a paradigm of resilient, high-velocity intelligence.

According to Towards Healthcare, the cell and gene therapy cold chain logistics market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 2.53 billion in 2026 to approximately USD 9.37 billion by 2035. Estimated to grow at a CAGR of 15.64% starting from 2026 to 2035.Cold chain logistics are intended to meet the particular requirements of cell or gene therapy and involve storage temperature requirements, packaging services, and transportation approaches. Particular tools, a dedicated infrastructure, and working technology provide consistent temperature control during storage, transportation, and management.

About Peli BioThermal

Peli BioThermal is the global partner to the life sciences organization, providing temperature-controlled packaging and solutions that protect biopharmaceuticals, biologics, vaccines, and well-developed therapies during transport. With a global network of solutions centers and proven services covering all temperature ranges, Peli BioThermal supports clinical trials, profitable distribution, and evolving therapies, ensuring medicines reach patients safely.

About PAXAFE

PAXAFE is a GxP cold chain decision intelligence & quality compliance platform that eliminates silos, digitizes and automates compliance workflows, and empowers teams with contextual intelligence to protect product, reduce cost, and drive toward zero waste.

A recent report by Towards Healthcare highlights that the cell and gene therapy cold chain logistics market is growing. Cold chain solutions help to maintain the integrity, potency, and quality of the cell and gene therapy drugs by keeping them at the correct temperature range.  These therapies are tremendously temperature sensitive, and even modest differences might result in the loss of medicinal qualities. Cold chain services for storage and distribution are significant for preserving the integrity, potency, and quality of cell and gene therapy medicine. It provides considerable advantages to manufacturers and distributors.